ArticleJournal of inflammation research2025
Glasgow Prognostic Score Serves as a Prognostic Factor of Clinical Outcome in Patients with Newly Diagnosed Multiple Myeloma.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glasgow Prognostic Score and Gustave Roussy Immune Score in Hodgkin Lymphoma: Survival Associations and Limited Incremental Prognostic Value Beyond the International Prognostic Score.Journal of clinical medicine · 2026Article
- Interpretable machine learning model for predicting postoperative hypoproteinemia in middle-aged and elderly patients following total joint arthroplasty: a multicenter retrospective study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The Glasgow Prognostic Score (GPS), a systemic inflammation-based prognostic model incorporating C-reactive protein (CRP) and serum albumin levels, has been widely validated in solid tumors and several hematologic malignancies. However, its prognostic value in newly diagnosed multiple myeloma (NDMM) remains unclear. This study aimed to evaluate the association between GPS and survival outcomes in NDMM patients. Patients and Methods: We retrospectively analyzed a real-world cohort of 865 NDMM patients. Patients were stratified based on GPS, and overall survival (OS) and progression-free survival (PFS) were assessed by using Kaplan-Meier analysis. Cox proportional hazards models were used to determine the independent prognostic significance of GPS, adjusting for confounding factors. To compare the prognostic stratification capacity of GPS to its two modified variants, the same Kaplan-Meier analysis was applied to evaluate both the modified Glasgow Prognostic Score (mGPS) and the hypersensitivity-modified Glasgow Prognostic Score (Hs-mGPS). Quantitative comparisons utilized area under the curve (AUC) values derived from time-dependent Receiver Operating Characteristic (ROC) analysis. Results: A higher GPS was significantly associated with inferior OS and PFS in NDMM patients. Multivariate analysis confirmed that GPS was an independent prognostic factor after adjusting for disease stage and other clinical variables. Additionally, patients with elevated GPS scores presented with more advanced disease stages, as reflected by higher Durie-Salmon and International Staging System (ISS) classifications. And GPS exerts better prognostic stratification capacity than mGPS and Hs-mGPS. Conclusion: The baseline GPS at the time of diagnosis is an independent prognostic factor that negatively relates to the MM patient survival, for which GPS may serve as a supplement tool in risk stratification upon the primary medical assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.